PHANES BIOTECH, INC.

Biotech · Private

Humanized monoclonal antibodies targeting tau pathology for Alzheimer's disease treatment

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$554K
Federal grants
$554K
2 awards · 2022–2023
Rank in peer group#212 of 502
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
3 pending

Capital timeline

20222023FEDERAL ↑EQUITY ↓Cumulative $554K$500K$54K
20222023FEDERAL ↑EQUITY ↓Cumulative $554K$500K$54K

Latest events

  • Federal grantHealth and Human S · Phase I · Treatment of Alzheimer's disease by clearing both tau and amyloid beta pathologies$54K
  • Federal grantHealth and Human S · Phase I · Treatment of Alzheimer's disease by clearing both tau and amyloid beta pathologies$500K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#212 · top 42%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 3
  • PendingHyperphosphorylated Tau Binding To Normal Tau As A Biomarker For Alzheimer's Disease Pathology And Related TauopathiesUSPTOApplication 63631943
  • PendingHyperphosphorylated Tau Binding To Normal Tau As A Biomarker For Alzheimer's Disease Pathology And Related TauopathiesUSPTOApplication 63575585
  • PendingHyperphosphorylated Tau Binding To Normal Tau As A Biomarker For Alzheimer's Disease Pathology And Related TauopathiesUSPTOApplication 63589273

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .